ResMed in 2026: Refined Focus, Margin Expansion, and the Stakes of Digital Health Leadership

ResMed’s latest results highlight both the benefits and the stakes of its strategic pivot toward core sleep and breathing health markets. With the MatrixCare divestiture complete and new acquisitions expanding its clinical and diagnostic reach, ResMed saw margin and earnings improvements alongside continued investment in product innovation. The company’s ability to leverage its digital health platform, maintain pricing power, and drive patient adherence will be central as it navigates regulatory, competitive, and technology-driven change.

Margin Gains and Portfolio Realignment Shape the Current Narrative

ResMed reported net revenue of $1.415 billion for Q1 FY2027, a 6% year-over-year increase, with the Sleep and Breathing Health segment growing 8% to $1.26 billion. This growth was primarily attributed to increased demand and unit sales of devices and masks. Gross margin improved to 61.5% from 61.2%, reflecting manufacturing efficiencies and lower amortization following the sale of MatrixCare. The divestiture, completed in September 2026, marked a strategic shift toward focusing on core growth areas. Meanwhile, R&D expenses rose 15% to $103 million, underscoring ResMed’s commitment to ongoing product innovation. [S2] The company’s diluted EPS climbed to $2.92 from $2.37 in the prior year period. [S2]

How ResMed’s Hybrid Model Drives Earnings Power

ResMed’s business model blends high-volume hardware (CPAP devices, masks, ventilators) with software-enabled services and cloud-based health applications. The hardware side typically benefits from scale, with manufacturing efficiencies supporting gross margins, particularly as device and mask volumes rise. The company’s Q1 gross margin improvement, even after portfolio changes, suggests that manufacturing cost control and the exit from lower-margin software (MatrixCare) are boosting profitability. [S2]

On the software and digital health side, ResMed’s value proposition rests on enabling clinicians to manage patients more efficiently and promoting therapy adherence. While pure software margins are often higher, the company’s remaining Residential Care Software business experienced a revenue drop post-MatrixCare sale, highlighting the dependence on scale and product breadth for software economics. The recurring element comes from ongoing device usage (replacement masks, consumables) and cloud-based patient management, which, if adoption and adherence remain high, can provide stable revenue streams.

R&D intensity (7.3% of net revenues in Q1) signals continued investment in innovation, which is essential for defending pricing and mitigating commoditization risk as technology evolves. Capital needs are moderate, with a $1.01 billion cash balance and a reported current ratio of 2.65. [S2] Future funding requirements are likely to be driven by R&D, select acquisitions, and potential manufacturing expansion, rather than dramatic fixed-capital outlays.

Defensible Ecosystem or Vulnerable Platform? Competitive Dynamics in Sleep Health

ResMed’s competitive edge historically derives from its global scale, broad product suite, and integration of AI-enabled, cloud-connected devices with clinician-facing software. These features can generate meaningful switching costs for providers who value integrated patient management and for patients accustomed to ResMed’s device ecosystem. However, the medical device and digital health space is seeing increased competition: established device manufacturers, new digital health entrants, and alternative therapy providers are all targeting sleep and respiratory care.

The move to divest MatrixCare trims the software portfolio but sharpens focus. This could be a double-edged sword: on one hand, it allows deeper investment in core growth areas and potentially faster innovation cycles; on the other, it reduces diversification and may expose the company to more concentrated regulatory or reimbursement risk. The ability to integrate new diagnostic platforms (e.g., from the VirtuOx acquisition) and extend into adjacent indications (like restless legs syndrome via Noctrix Health) may help offset some of this exposure.

Clinical evidence and regulatory approvals continue to provide barriers to entry, but rapid technology change and evolving reimbursement rules are eroding pure product-based moats. The company’s future defensibility may hinge on its ability to leverage real-world data, maintain clinician loyalty, and keep patient adherence rates high.

Unlocking New Growth Through Digital Adherence and Global Expansion

ResMed’s most favorable scenario involves sustained global growth in sleep apnea and respiratory device adoption, amplified by improved patient adherence enabled through its AI-powered, cloud-connected ecosystem. If the company can demonstrate that innovations like the AirSense 11 (with touch screen and over-the-air updates) materially boost adherence and clinical outcomes, this would reinforce device and consumable demand and lock in high-margin recurring revenue.

Further upside could come from successful integration of recent acquisitions (VirtuOx, Noctrix Health), expanding the diagnostic funnel and capturing new patient populations, including those with restless legs syndrome. Geographic expansion, especially in underpenetrated regions, may amplify volume growth if reimbursement and regulatory environments are supportive.

Confirmation would come from accelerating device and mask sales, rising software-enabled service revenues, and evidence of improved patient adherence metrics (if disclosed). Gross margin expansion alongside rising R&D spend would also signal sustained innovation-driven pricing power.

Core Device Growth Balances Software Transition and Execution Risks

The most plausible outcome is steady mid-single-digit revenue growth anchored by continued global demand for sleep and breathing health devices, offset by slower growth or volatility in the software segment post-MatrixCare sale. Device mix and consumable sales are likely to remain the primary earnings drivers, with incremental gross margin gains from manufacturing efficiencies and product enhancements.

The Residential Care Software segment may see subdued or uneven growth as the company rebuilds scale and focus in remaining verticals. R&D investment is expected to continue, supporting incremental innovation but also pressuring operating expenses. Regulatory changes and payer dynamics will likely remain headwinds, but not overwhelming ones unless there are significant shifts in reimbursement or clinical guidelines.

This scenario would be confirmed by stable or gradually increasing device and mask volumes, gross margin maintenance in the low-60% range, and R&D as a consistent share of revenue. Evidence of retention or improvement in patient adherence rates, if disclosed, would support the base case.

Margin Compression and Execution Stumbles in a Shifting Regulatory Landscape

A negative scenario could arise if supply chain disruptions or inflationary pressures drive up input costs, eroding gross margins despite manufacturing efficiencies. If ResMed struggles to convert R&D investment into commercially successful products, or if new digital health competitors capture share through lower-cost or more engaging platforms, both revenue growth and profitability could stall.

Regulatory or reimbursement changes—such as tighter coverage for CPAP therapy or new requirements for digital health data—could further pressure adoption and pricing. The loss of software scale post-MatrixCare could leave the company more exposed to volatility in its core device markets. Persistent patient adherence challenges, particularly if new solutions fail to move the needle, would compound these risks.

This scenario would be corroborated by declining or flat core device sales, gross margin reversion, rising operating expenses without offsetting revenue growth, and any signs of increased churn or reduced patient engagement (if disclosed).

Signals That Will Clarify ResMed’s Long-Term Value Creation

Growth rate in global device and mask sales volumes, as this remains the primary top-line driver post-MatrixCare divestiture.

Trends in software-enabled service revenue and the company’s ability to rebuild momentum in the Residential Care Software segment.

Gross margin trajectory, particularly in the face of input cost volatility and as manufacturing efficiencies mature.

R&D expense as a percentage of revenue, and evidence that this spend is translating into commercially successful product launches.

Updates on patient adherence rates and therapy engagement metrics, if disclosed, as these directly affect recurring revenue potential.

Integration progress and revenue contribution from recent acquisitions (VirtuOx, Noctrix Health), especially in expanding the addressable market.

Regulatory and reimbursement developments in major markets that could alter the economics of sleep and respiratory care.

Disclaimer: This is research-only, informational analysis and not investment advice. It may include AI-generated interpretation and general industry context. Always verify important details using primary sources.